Frontiers in medicine · 2024
Distinct metabolomic and lipidomic profiles in serum samples of patients with primary sclerosing cholangitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fererberger Tanja, Buechler Christa, Kandulski Arne, Elger Tanja, Loibl Johanna, Schmid Stephan, Sommersberger Stefanie, Gunawan Stefan, Zundler Sebastian, Huss Muriel, Bettenworth Dominik, Kempa Sally, Weidlich Simon, Föh Bandik, Huang Xinyu, Grzegorzek Marcin, Derer-Petersen Stefanie, Günther Ulrich L, Marquardt Jens U, Kunst Claudia, Gülow Karsten, Müller Martina, Sina Christian, Schmelter Franziska, Tews Hauke C
Аннотация
INTODUCTION: Identification of specific metabolome and lipidome profile of patients with primary sclerosing cholangitis (PSC) is crucial for diagnosis, targeted personalized therapy, and more accurate risk stratification.
METHODS: Nuclear magnetic resonance (NMR) spectroscopy revealed an altered metabolome and lipidome of 33 patients with PSC [24 patients with inflammatory bowel disease (IBD) and 9 patients without IBD] compared with 40 age-, sex-, and body mass index (BMI)-matched healthy controls (HC) as well as 64 patients with IBD and other extraintestinal manifestations (EIM) but without PSC.
RESULTS: In particular, higher concentrations of pyruvic acid and several lipoprotein subfractions were measured in PSC in comparison to HC. Of clinical relevance, a specific amino acid and lipid profile was determined in PSC compared with IBD and other EIM.
DISCUSSION: These results have the potential to improve diagnosis by differentiating PSC patients from HC and those with IBD and EIM.
METHODS: Nuclear magnetic resonance (NMR) spectroscopy revealed an altered metabolome and lipidome of 33 patients with PSC [24 patients with inflammatory bowel disease (IBD) and 9 patients without IBD] compared with 40 age-, sex-, and body mass index (BMI)-matched healthy controls (HC) as well as 64 patients with IBD and other extraintestinal manifestations (EIM) but without PSC.
RESULTS: In particular, higher concentrations of pyruvic acid and several lipoprotein subfractions were measured in PSC in comparison to HC. Of clinical relevance, a specific amino acid and lipid profile was determined in PSC compared with IBD and other EIM.
DISCUSSION: These results have the potential to improve diagnosis by differentiating PSC patients from HC and those with IBD and EIM.